Brokerage firm Jefferies Maintains its rating on Merck & Co.(NYSE:MRK). In a research note issued to the investors, the brokerage major Raises the price-target to $53.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Jul 14, 2016.
In a different note, On Jun 14, 2016, Jefferies said it Maintains its rating on Merck & Co.. In the research note, the firm Lowers the price-target to $54.00 per share. The shares have been rated ‘Hold’ by the firm. On May 9, 2016, Credit Suisse said it Maintains its rating on Merck & Co.. In the research note, the firm Raises the price-target to $56.00 per share. The shares have been rated ‘Neutral’ by the firm.
Merck & Co. (MRK) shares turned negative on Mondays trading session with the shares closing down -0.61 points or -1.02% at a volume of 87,69,171. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $59.49. The peak price level was also seen at $59.49 while the days lowest was $58.715. Finally the shares closed at $59.02. The 52-week high of the shares is $60.07 while the 52-week low is $45.69. According to the latest information available, the market cap of the company is $163,369 M.
Merck & Co.(MRK) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $9.31B. Analysts had an estimated revenue of $9.46B. Earnings per share were $0.89. Analysts had estimated an EPS of $0.85.
Several Insider Transactions has been reported to the SEC. On Jul 5, 2016, Weir Mirian M Graddick (Exe V-P, HR) sold 45,000 shares at $57.96 per share price.Also, On Jul 5, 2016, Kenneth C Frazier (Chairman, President & CEO) sold 60,000 shares at $58.00 per share price.On Jul 1, 2016, Adam H Schechter (EVP & Pres-Global Human Health) sold 50,000 shares at $57.69 per share price, according to the Form-4 filing with the securities and exchange commission.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.